[Edaily Reporter KIM SUNG-JIN ] NIBEC CO., LTD.(138610)is seeking to expand its collaboration with global pharmaceutical companies. The company plans to discuss partnerships focused on obesity treatments that simultaneously target body fat reduction and muscle mass preservation, as well as treatments for cardiovascular and renal diseases that induce the regeneration of damaged organs.

NIBEC CO., LTD. announced that it will participate in “BIO-Europe 2026,” a global biotech partnering event taking place in Cologne, Germany, for three days starting on the 9th. BIO-Europe is an event where global pharmaceutical companies, biotech firms, and investment institutions gather to discuss technology transfer, joint development, and strategic partnerships for new drug candidates. At this event, NIBEC CO., LTD. plans to introduce its peptide-based new drug pipeline and proprietary drug delivery platform technology, and discuss collaboration opportunities with global companies.

One of the key collaboration targets is “Regenotide,” a drug candidate for the treatment of obesity and metabolic diseases. Regenotide is a peptide-based drug candidate currently in development with the goal of reducing body fat while preserving muscle mass. It focuses on addressing the issue of muscle loss during weight loss—a limitation often cited in existing obesity treatments.

NIBEC CO., LTD. is currently preparing for Regenotide to enter Phase 2 clinical trials in the U.S. and is planning not only monotherapy but also combination therapy with GLP-1-based obesity treatments. The company is also exploring ways to expand the indications to include obesity-related metabolic disorders and is considering the development of an oral formulation.

In the field of cardiovascular and renal diseases, the company is introducing a new peptide drug candidate. It aims to restore and regenerate damaged heart and kidney tissue. While existing treatments have focused on inhibiting disease progression or managing symptoms, NIBEC CO., LTD. is developing a therapeutic strategy that promotes the recovery of damaged tissue to improve organ function. Based on research results obtained during the preclinical phase, the company plans to discuss the possibility of follow-up research and joint development with global pharmaceutical companies. Previously, in October, NIBEC CO., LTD. announced at a conference held in Boston that it had confirmed the potential of its compounds to alleviate kidney damage and cardiac fibrosis caused by chronic kidney disease.

NIBEC CO., LTD. official stated, “At this year’s BioEurope, we plan to discuss a wide range of collaboration opportunities with global pharmaceutical and biotech companies based on our diverse pipeline of peptide-based new drugs and our proprietary drug delivery platform technology.” The official added, “In particular, we will actively seek technology transfer and joint development opportunities, focusing on the differentiated potential of Regenotide for obesity treatment and our research achievements in therapies for cardiovascular and renal diseases centered on tissue regeneration.”